Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Su, Zhen"'
Autor:
Xinyue Hu, Xiujun Liu, Lianqi Sun, Yong-Su Zhen, Yi Li, Jie Jin, Yanping Li, Yu‐cheng Wang, Qingfang Miao, Rong Wang, Zhuorong Li, A-Long Cui
Publikováno v:
Molecular Oncology
Molecular Oncology, Vol 13, Iss 2, Pp 246-263 (2019)
Molecular Oncology, Vol 13, Iss 2, Pp 246-263 (2019)
Epidermal growth factor receptor (EGFR) is a rational target for cancer therapy, because its overexpression plays an important oncogenic role in a variety of solid tumors; however, EGFR-targeted antibody-drug conjugate (ADC) therapy for esophageal sq
Autor:
Guang-Lei Ma, Juan Xiong, Junmin Li, Jin-Feng Hu, Xi-Ling Wang, Su-Zhen Dong, Nan Guo, Ze-Xin Jin, Yuqiao Han
Publikováno v:
Bioorganic chemistry. 105
Rare and endangered plants (REPs) and their associated endophytes survived in unique habitats are promising sources for natural product-derived drug discovery. In this study, six new (cephaloverines A–F, 1–6, resp.) and 16 known (11–26) cephalo
Publikováno v:
Oncotarget
// Bing-yan Zhu 1 , Bo-yang Shang 1 , Yue Du 1 , Yi Li 1 , Liang Li 1 , Xian-dong Xu 1 , Yong-su Zhen 1 1 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China Correspondence
Publikováno v:
Journal of Cancer Research and Therapeutics, Vol 12, Iss 1, Pp 182-187 (2016)
Aims: The aim of this study is to explore the antitumor efficacy of lidamycin (LDM) against human multiple myelomas (MM). Materials and Methods: Human MM RPMI 8226 cells and the xenograft model in nonobese diabetic/severe combined immunodeficient (NO
Publikováno v:
Cancer Chemotherapy and Pharmacology. 69:1323-1332
As reported, epidermal growth factor receptor (EGFR) is over expressed in a variety of cancers including esophageal squamous cell carcinoma. Therefore, it becomes one of the potential targets for treating esophageal cancer. Pingyangmycin (PYM), a sin
Publikováno v:
Acta Pharmacologica Sinica. 30:1025-1032
To investigate the effects of lidamycin (LDM) on a mouse myeloma cell line (SP2/0) and human multiple myeloma cell lines (U266 and SKO-007), and provide the basis for the use of LDM in cancer therapy.A 3-[4,5-dimethylthiazol-2-yl]5-[3-carboxymethoxyp
Publikováno v:
The American Journal of Chinese Medicine. 37:923-931
In previous studies, rhein, one of the major bioactive constituents in the rhizome of rhubarb, inhibited the proliferation of various human cancer cells. However, because of its water insolubility, the anti-tumor efficacy of rhein was limited in vivo
Publikováno v:
Acta Pharmacologica Sinica. 29:614-619
Aim: To investigate the effects on human pancreatic cancer PANC-1 and SW1990 cells using a combination of lidamycin (LDM) and gemcitabine. Methods: A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was used to determine the growth
Publikováno v:
Cancer immunology, immunotherapy : CII. 63(12)
Tuftsin (TF) is an immunomodulator tetrapeptide (Thr-Lys-Pro-Arg) that binds to the receptor neuropilin-1 (Nrp1) on the surface of cells. Many reports have described anti-tumor activity of tuftsin to relate with nonspecific activation of the host imm
Publikováno v:
Journal of pharmaceutical sciences. 103(4)
We have chemically synthesized NGR-LDP-PYM, a novel CD13/aminopeptidase (APN)-targeting and hydrolase-resistant conjugate by cross-linking of the antitumor antibiotic pingyangmycin (bleomycin A5, PYM) to an engineered NGR motif-integrated apoprotein